MD; Newton, PN (2015) A Repeat Random Survey of the Prevalence of Falsified and Substandard Antimalarials in the Lao PDR: A Change

In 2003, a stratified random sample survey was conducted in the Lao People’s Democratic Republic (Laos) to study the availability and quality of antimalarials in the private sector. In 2012, this survey was repeated to allow a statistically valid analysis of change through time. The counterfeit detection device 3 (CD-3) was used to assess packaging quality in the field and HPLC and mass spectroscopy analysis chemical analysis performed. The availability of oral artesunate monotherapies had significantly decreased from 22.9% (22) of 96 outlets in southern Laos in 2003 to 4.8% (7) of 144 outlets in 2012 (P < 0.0001). All the samples collected in the 2012 survey contained the correct active pharmaceutical ingredients (APIs) in contrast to the 21 (84%) falsified artesunate samples found in the 2003 survey. Although none of the medicines found in 2012 survey had evidence for falsification, 25.4% (37) of the samples were outside the 90–110% pharmacopeial limits of the label claim, suggesting that they were substandard or degraded. Results obtained from this survey show that patients are still exposed to poorly manufactured drugs or to ineffective medicines such as chloroquine. The quality of artemisinin-based combination therapies (ACTs) used in Laos needs to be monitored, since falsified ACTs would have devastating consequences in public health.

[1]  Nicola Ranieri,et al.  Evaluation of a New Handheld Instrument for the Detection of Counterfeit Artesunate by Visual Fluorescence Comparison , 2014, The American journal of tropical medicine and hygiene.

[2]  J. Skarbinski,et al.  Return of widespread chloroquine-sensitive Plasmodium falciparum to Malawi. , 2014, The Journal of infectious diseases.

[3]  P. Newton,et al.  Falsified medicines in Africa: all talk, no action. , 2014, The Lancet. Global health.

[4]  D. Kwiatkowski,et al.  Spread of artemisinin resistance in Plasmodium falciparum malaria. , 2014, The New England journal of medicine.

[5]  Patricia Tabernero,et al.  Mind the gaps - the epidemiology of poor-quality anti-malarials in the malarious world - analysis of the WorldWide Antimalarial Resistance Network database , 2014, Malaria Journal.

[6]  B. Venhuis,et al.  Dose-to-dose variations with single packages of counterfeit medicines and adulterated dietary supplements as a potential source of false negatives and inaccurate health risk assessments. , 2014, Journal of pharmaceutical and biomedical analysis.

[7]  H. Tsuboi,et al.  Effects of packaging and storage conditions on the quality of amoxicillin-clavulanic acid – an analysis of Cambodian samples , 2013, BMC Pharmacology and Toxicology.

[8]  M. Boelaert,et al.  Poor‐quality medical products: time to address substandards, not only counterfeits , 2012, Tropical medicine & international health : TM & IH.

[9]  K. Moji,et al.  Joint malaria surveys lead towards improved cross-border cooperation between Savannakhet province, Laos and Quang Tri province, Vietnam , 2012, Malaria Journal.

[10]  P. Newton,et al.  Efficacy of artemether-lumefantrine, the nationally-recommended artemisinin combination for the treatment of uncomplicated falciparum malaria, in southern Laos , 2012, Malaria Journal.

[11]  A. Carpentier,et al.  Update on counterfeit antibiotics worldwide; public health risks. , 2012, Medecine et maladies infectieuses.

[12]  P. Newton,et al.  The WWARN Antimalarial Quality Surveyor , 2012, Pathogens and global health.

[13]  Mayfong Mayxay,et al.  No Evidence for Spread of Plasmodium falciparum Artemisinin Resistance to Savannakhet Province, Southern Laos , 2012, The American journal of tropical medicine and hygiene.

[14]  T. Wellems,et al.  The threat of artemisinin-resistant malaria. , 2011, The New England journal of medicine.

[15]  Paul N. Newton,et al.  Poor quality drugs: grand challenges in high throughput detection, countrywide sampling, and forensics in developing countries. , 2011, The Analyst.

[16]  C. Torres Counterfeiting goes cinematic in public campaigns , 2010, Nature Medicine.

[17]  B. Hongvanthong,et al.  High heterogeneity in Plasmodium falciparum risk illustrates the need for detailed mapping to guide resource allocation: a new malaria risk map of the Lao People's Democratic Republic , 2010, Malaria Journal.

[18]  R. Maude,et al.  Hyperparasitaemia and low dosing are an important source of anti-malarial drug resistance , 2009, Malaria Journal.

[19]  Christina Y Hampton,et al.  A stratified random survey of the proportion of poor quality oral artesunate sold at medicine outlets in the Lao PDR – implications for therapeutic failure and drug resistance , 2009, Malaria Journal.

[20]  P. Newton,et al.  Characterization of "Yaa Chud" Medicine on the Thailand-Myanmar border: selecting for drug-resistant malaria and threatening public health. , 2008, The American journal of tropical medicine and hygiene.

[21]  P. Newton,et al.  Impaired clinical response in a patient with uncomplicated falciparum malaria who received poor-quality and underdosed intramuscular artemether. , 2008, The American journal of tropical medicine and hygiene.

[22]  Christina Y Hampton,et al.  A Collaborative Epidemiological Investigation into the Criminal Fake Artesunate Trade in South East Asia , 2008, PLoS medicine.

[23]  Henry Nettey,et al.  Use of refractometry and colorimetry as field methods to rapidly assess antimalarial drug quality. , 2007, Journal of pharmaceutical and biomedical analysis.

[24]  P. Newton,et al.  Characterization of Solid Counterfeit Drug Samples by Desorption Electrospray Ionization and Direct‐analysis‐in‐real‐time Coupled to Time‐of‐flight Mass Spectrometry , 2006, ChemMedChem.

[25]  Peter Aldhous,et al.  Counterfeit pharmaceuticals: Murder by medicine , 2005, Nature.

[26]  M. Mayxay,et al.  Fake antimalarials in Southeast Asia are a major impediment to malaria control: multinational cross‐sectional survey on the prevalence of fake antimalarials , 2004, Tropical medicine & international health : TM & IH.

[27]  B. Lindgren,et al.  The quality of drugs in private pharmacies in Lao PDR: a repeat study in 1997 and 1999 , 2004, Pharmacy World and Science.

[28]  T. Kenyon,et al.  Substandard tuberculosis drugs on the global market and their simple detection. , 2001, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[29]  P. Newton,et al.  Melioidosis and Pandora's box in the Lao People's Democratic Republic. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[30]  B. Eriksson,et al.  Real world pharmacy: assessing the quality of private pharmacy practice in the Lao People's Democratic Republic. , 2001, Social science & medicine.

[31]  S. Phanouvong,et al.  The State of Medicine Quality in the Mekong Sub-Region , 2014 .

[32]  B. Lindgren,et al.  The quality of drugs in private pharmacies in the Lao People’s Democratic Republic , 1998 .

[33]  G. Tomson,et al.  Pharmaceutical regulation in context: the case of Lao People's Democratic Republic. , 1997, Health policy and planning.